Literature DB >> 8350415

V3 loop of the human immunodeficiency virus type 1 Env protein: interpreting sequence variability.

L Milich1, B Margolin, R Swanstrom.   

Abstract

Two different states of human immunodeficiency virus type 1 are apparent in the asymptomatic and late stages of infection. Important determinants associated with these two states have been found within the V3 loop of the viral Env protein. In this study, two large data sets of published V3 sequences were analyzed to identify patterns of sequence variability that would correspond to these two states of the virus. We were especially interested in the pattern of basic amino acid substitutions, since the presence of basic amino acids in V3 has been shown to change virus tropism in cell culture. Four features of the sequence heterogeneity in V3 were observed: (i) approximately 70% of all nonconservative basic substitutions occur at four positions in V3, and V3 sequences with a basic substitution in at least one of these four positions contain approximately 95% of all nonconservative basic substitutions; (ii) substitution patterns within V3 are influenced by the identity of the amino acid at position 25; (iii) sequence polymorphisms account for a significant fraction of uncharged amino acid substitutions at several positions in V3, and sequence heterogeneity other than these polymorphisms is most significant at two positions near the tip of V3; and (iv) sequence heterogeneity in V3 (in addition to the basic amino acid substitutions) is approximately twofold greater in V3 sequences that contain basic amino acid substitutions. By using this sequence analysis, we were able to identify distinct groups of V3 sequences in infected patients that appear to correspond to these two virus states. The identification of these discrete sequence patterns in vivo demonstrates how the V3 sequence can be used as a genetic marker for studying the two states of human immunodeficiency virus type 1.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8350415      PMCID: PMC237966     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  79 in total

1.  High efficiency transformation of E. coli by high voltage electroporation.

Authors:  W J Dower; J F Miller; C W Ragsdale
Journal:  Nucleic Acids Res       Date:  1988-07-11       Impact factor: 16.971

2.  Envelope sequences of two new United States HIV-1 isolates.

Authors:  C Gurgo; H G Guo; G Franchini; A Aldovini; E Collalti; K Farrell; F Wong-Staal; R C Gallo; M S Reitz
Journal:  Virology       Date:  1988-06       Impact factor: 3.616

3.  Neutralizing antibodies to an immunodominant envelope sequence do not prevent gp120 binding to CD4.

Authors:  M A Skinner; A J Langlois; C B McDanal; J S McDougal; D P Bolognesi; T J Matthews
Journal:  J Virol       Date:  1988-11       Impact factor: 5.103

4.  Differential syncytium-inducing capacity of human immunodeficiency virus isolates: frequent detection of syncytium-inducing isolates in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex.

Authors:  M Tersmette; R E de Goede; B J Al; I N Winkel; R A Gruters; H T Cuypers; H G Huisman; F Miedema
Journal:  J Virol       Date:  1988-06       Impact factor: 5.103

5.  Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees.

Authors:  J Goudsmit; C Debouck; R H Meloen; L Smit; M Bakker; D M Asher; A V Wolff; C J Gibbs; D C Gajdusek
Journal:  Proc Natl Acad Sci U S A       Date:  1988-06       Impact factor: 11.205

6.  Characterization of a human immunodeficiency virus neutralizing monoclonal antibody and mapping of the neutralizing epitope.

Authors:  S Matsushita; M Robert-Guroff; J Rusche; A Koito; T Hattori; H Hoshino; K Javaherian; K Takatsuki; S Putney
Journal:  J Virol       Date:  1988-06       Impact factor: 5.103

7.  An immunodominant epitope of the human immunodeficiency virus envelope glycoprotein gp160 recognized by class I major histocompatibility complex molecule-restricted murine cytotoxic T lymphocytes.

Authors:  H Takahashi; J Cohen; A Hosmalin; K B Cease; R Houghten; J L Cornette; C DeLisi; B Moss; R N Germain; J A Berzofsky
Journal:  Proc Natl Acad Sci U S A       Date:  1988-05       Impact factor: 11.205

8.  Distinct replicative and cytopathic characteristics of human immunodeficiency virus isolates.

Authors:  E M Fenyö; L Morfeldt-Månson; F Chiodi; B Lind; A von Gegerfelt; J Albert; E Olausson; B Asjö
Journal:  J Virol       Date:  1988-11       Impact factor: 5.103

9.  Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120.

Authors:  J R Rusche; K Javaherian; C McDanal; J Petro; D L Lynn; R Grimaila; A Langlois; R C Gallo; L O Arthur; P J Fischinger
Journal:  Proc Natl Acad Sci U S A       Date:  1988-05       Impact factor: 11.205

10.  Extensive variation of human immunodeficiency virus type-1 in vivo.

Authors:  M S Saag; B H Hahn; J Gibbons; Y Li; E S Parks; W P Parks; G M Shaw
Journal:  Nature       Date:  1988-08-04       Impact factor: 49.962

View more
  68 in total

1.  Distinct human immunodeficiency virus strains in the bone marrow are associated with the development of thrombocytopenia.

Authors:  F Voulgaropoulou; B Tan; M Soares; B Hahn; L Ratner
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

2.  Characterisation of near-full length genome sequences of three South African human immunodeficiency virus type 1 subtype C isolates.

Authors:  Gillian M Hunt; Maria A Papathanasopoulos; Glenda E Gray; Caroline T Tiemessen
Journal:  Virus Genes       Date:  2003-01       Impact factor: 2.332

3.  A novel denaturing heteroduplex tracking assay for genotypic prediction of HIV-1 tropism.

Authors:  Binshan Shi; Barbara Weiser; Linda M Styer; Kimdar Kemal; Cheryl Brunner; Kathryn Anastos; Harold Burger
Journal:  J Virol Methods       Date:  2012-06-21       Impact factor: 2.014

4.  Evolutionary variants of the human immunodeficiency virus type 1 V3 region characterized by using a heteroduplex tracking assay.

Authors:  J A Nelson; S A Fiscus; R Swanstrom
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

5.  Inhibition of human immunodeficiency virus infection by agents that interfere with thiol-disulfide interchange upon virus-receptor interaction.

Authors:  H J Ryser; E M Levy; R Mandel; G J DiSciullo
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-10       Impact factor: 11.205

6.  Antibodies of symptomatic human immunodeficiency virus type 1-infected individuals are directed to the V3 domain of noninfectious and not of infectious virions present in autologous serum.

Authors:  M Schreiber; H Petersen; C Wachsmuth; H Müller; F T Hufert; H Schmitz
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

7.  In vivo distribution and cytopathology of variants of human immunodeficiency virus type 1 showing restricted sequence variability in the V3 loop.

Authors:  Y K Donaldson; J E Bell; E C Holmes; E S Hughes; H K Brown; P Simmonds
Journal:  J Virol       Date:  1994-09       Impact factor: 5.103

Review 8.  The human immunodeficiency virus type 1 (HIV-1) CD4 receptor and its central role in promotion of HIV-1 infection.

Authors:  S Bour; R Geleziunas; M A Wainberg
Journal:  Microbiol Rev       Date:  1995-03

9.  A naturally occurring single basic amino acid substitution in the V3 region of the human immunodeficiency virus type 1 env protein alters the cellular host range and antigenic structure of the virus.

Authors:  T Shioda; S Oka; S Ida; K Nokihara; H Toriyoshi; S Mori; Y Takebe; S Kimura; K Shimada; Y Nagai
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

10.  Compartmentalization of human immunodeficiency virus type 1 between blood monocytes and CD4+ T cells during infection.

Authors:  Jennifer A Fulcher; Yon Hwangbo; Rafael Zioni; David Nickle; Xudong Lin; Laura Heath; James I Mullins; Lawrence Corey; Tuofu Zhu
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.